These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Intraperitoneal administration of shiga toxin type 2 in rats in the late stage of pregnancy produces premature delivery of dead fetuses. Burdet J; Zotta E; Franchi AM; Ibarra C Placenta; 2009 Jun; 30(6):491-6. PubMed ID: 19395083 [TBL] [Abstract][Full Text] [Related]
28. Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome. Ohara S; Kawasaki Y; Abe Y; Watanabe M; Ono A; Suyama K; Hashimoto K; Honda T; Suzuki J; Hosoya M Am J Nephrol; 2012; 36(6):516-23. PubMed ID: 23171542 [TBL] [Abstract][Full Text] [Related]
29. [Effects of silencing transforming growth factor-beta1 by RNAi upon transdifferentiation of renal allograft tubular epithelial cells in rats]. Xia YG; Wu XH; Yin ZK; Luo CL; Zhang JM; Cheng HL Zhonghua Yi Xue Za Zhi; 2009 Dec; 89(44):3151-5. PubMed ID: 20193281 [TBL] [Abstract][Full Text] [Related]
30. The role of the endothelium in hemolytic uremic syndrome. Zoja C; Morigi M; Remuzzi G J Nephrol; 2001; 14 Suppl 4():S58-62. PubMed ID: 11798147 [TBL] [Abstract][Full Text] [Related]
31. Verotoxin (shiga toxin) sensitizes renal epithelial cells to increased heme toxicity: possible implications for the hemolytic uremic syndrome. Bitzan M; Bickford BB; Foster GH J Am Soc Nephrol; 2004 Sep; 15(9):2334-43. PubMed ID: 15339982 [TBL] [Abstract][Full Text] [Related]
32. Association between hemolytic uremic syndrome and verotoxin-producing strains of E. coli. Jure MA; de Saab OA; de Castillo MC; Sesma F; Miceli S; Zamora AM; de Ruiz Holgado AP; de Nader OM Rev Latinoam Microbiol; 1998; 40(1-2):1-8. PubMed ID: 10932728 [TBL] [Abstract][Full Text] [Related]
33. A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease. Keepers TR; Psotka MA; Gross LK; Obrig TG J Am Soc Nephrol; 2006 Dec; 17(12):3404-14. PubMed ID: 17082244 [TBL] [Abstract][Full Text] [Related]
35. Mitomycin-induced hemolytic uremic kidney. An experimental model in the rat. Cattell V Am J Pathol; 1985 Oct; 121(1):88-95. PubMed ID: 3876775 [TBL] [Abstract][Full Text] [Related]
36. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
37. Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome. Ray PE; Liu XH; Xu L; Rakusan T Pediatr Nephrol; 1999 Sep; 13(7):586-93. PubMed ID: 10460507 [TBL] [Abstract][Full Text] [Related]
38. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792 [TBL] [Abstract][Full Text] [Related]
39. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195 [TBL] [Abstract][Full Text] [Related]